This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kribbs, S. B. Articles by Spinale, F. G. Search for Related Content PubMed PubMed Citation Articles by Kribbs, S. B. Articles by Spinale, F. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMLODIPINE BESYLATE Medline Plus Health Information Blood Pressure Medicines Heart Failure

(Hypertension. 1998;31:755-765.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Amlodipine Monotherapy, Angiotensin-Converting Enzyme Inhibition, and Combination Therapy With Pacing-Induced Heart Failure

Scott B. Kribbs; William M. Merritt; Mark J. Clair; R. Stephen Krombach; Ward V. Houck; Michael G. Dodd; Rupak Mukherjee; ; Francis G. Spinale

From the Division of Cardiothoracic Surgery (S.B.K., W.M.M., M.J.C., R.S.K., W.V.H., R.M., F.G.S.), Medical University of South Carolina (Charleston); and Pfizer Central Research (M.G.D.), Sandwich, UK.

Correspondence to Francis G. Spinale, MD, PhD, Cardiothoracic Surgery and Physiology, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC 29425-2279.

Abstract—In patients with congestive heart failure (CHF) receiving therapy with angiotensin-converting enzyme (ACE) inhibition, institution of calcium channel antagonism with amlodipine provided favorable effects. The goal of the present study was to define potential mechanisms for these effects by measuring left ventricular function, hemodynamics, and neurohormonal system activity in a model of CHF in which amlodipine treatment had been instituted either as a monotherapy or in combination with ACE inhibition. Thirty-two pigs were instrumented to allow measurement of cardiac index, total systemic resistance index, and neurohormonal activity in the conscious state and assigned to one of four groups: (1) rapid atrial pacing (240 bpm) for 3 weeks (n=8), (2) amlodipine (1.5 mg · kg^-1 · d^-1) and pacing (n=8), (3) ACE inhibition (fosinopril 1.0 mg/kg BID) and pacing (n=8), and (4) amlodipine and ACE inhibition (1.0 mg · kg^-1 · d^-1 and 1.0 mg/kg BID, respectively) and pacing (n=8). Measurements were obtained in the normal control state and after the completion of the treatment protocols. With rapid pacing, basal resting cardiac index was reduced compared with control values (2.7±0.2 versus 4.7±0.1 L · min^-1 · m^-2, respectively, P<.05) and increased from rapid pacing–only values with either amlodipine or combination therapy (3.7±0.3 and 4.4±0.5 L · min^-1 · m^-2, respectively, P<.05). Basal resting total systemic resistance index was higher in the rapid pacing–only group compared with control values (2731±263 versus 1721±53 dyne · s · cm^-5 · m², respectively, P<.05), was reduced with either amlodipine treatment or ACE inhibition (2125±226 and 2379±222 dyne · s · cm^-5 · m², respectively, P<.05), and was normalized with combination therapy. Plasma catecholamines, renin activity, and endothelin levels were increased threefold with rapid pacing. Amlodipine, either as a monotherapy or in combination with ACE inhibition, did not result in increased plasma catecholamines and renin activity compared with the rapid pacing–only group. Furthermore, combination therapy reduced steady state norepinephrine and normalized epinephrine levels. The results of the present study demonstrated that monotherapy with either amlodipine or ACE inhibition provides beneficial effects in this pacing model of CHF. Combined amlodipine and ACE inhibition provided greater benefit with respect to vascular resistance properties and neurohormonal system activity compared with either monotherapy.

Key Words: angiotensin-converting enzyme inhibition • amlodipine • heart failure • exercise • ventricular function, left

This article has been cited by other articles:

				R.P. Mason, P. Marche, and T.H. Hintze Novel Vascular Biology of Third-Generation L-Type Calcium Channel Antagonists: Ancillary Actions of Amlodipine Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2155 - 2163. [Abstract] [Full Text] [PDF]

				R. B. New, A. C. Sampson, M. K. King, J. W. Hendrick, M. J. Clair, J. H. McElmurray III, J. Mandel, R. Mukherjee, Marc de Gasparo, and F. G. Spinale Effects of Combined Angiotensin II and Endothelin Receptor Blockade With Developing Heart Failure : Effects on Left Ventricular Performance Circulation, September 19, 2000; 102(12): 1447 - 1453. [Abstract] [Full Text] [PDF]

				C. Wei and J. C. Burnett Jr. Inhibition by calcium antagonism of circulating and renal endothelin in experimental congestive heart failure Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H263 - H268. [Abstract] [Full Text] [PDF]

				F. G. Spinale, R. Mukherjee, R. S. Krombach, M. J. Clair, J. W. Hendrick, W. V. Houck, L. Hebbar, S. B. Kribbs, J. L. Zellner, and M. G. Dodd Chronic Amlodipine Treatment During the Development of Heart Failure Circulation, October 20, 1998; 98(16): 1666 - 1674. [Abstract] [Full Text] [PDF]